Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk

Tumor Biology

Volumn 34, Issue 5, 2013, Pages 2929-2936

  Zhang, Hongtuan ^a   Wang, Andi ^a,b   Ma, Hui ^a   Xu, Yong ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Key Laboratory of Medical Epigenetics   (China)

Author keywords

Association; Cancer; Insulin receptor substrate 1; Meta analysis; Polymorphism

Indexed keywords

EID: 84885428708     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0855-3     Document Type: Article

References (36)

1. Kanavos P. The rising burden of cancer in the developing world. Ann Oncol. 2006;17:viii15-23.
2. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4:850-60.
3. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359:2143-53.
4. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789-99.
5. Shpakov AO, Pertseva MN. Structural and functional characterization of insulin receptor substrate proteins and the molecular mechanisms of their interaction with insulin superfamily tyrosine kinase receptors and effector proteins. Membr Cell Biol. 2000;13:455-84.
6. Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet. 1999;23:32-40.
7. Waters SB, Pessin JE. Insulin receptor substrate 1 and 2 (IRS1 and IRS2): what a tangled web we weave. Trends Cell Biol. 1996;6:1-4.
8. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci. 2003;23:7084-92.
9. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915-28.
10. Jackson JG, White MF, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem. 1998;273:9994-10003.
11. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 2001;15:2099-111.
12. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene. 2000;19:5574-81.
13. Porzio O, Federici M, Hribal ML, Lauro D, Accili D, Lauro R, et al. The Gly972 Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. J Clin Invest. 1999;104:357-64.
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
16. Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT, et al. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res. 2009;11:R76.
17. Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, et al. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012;21:1362-70.
18. Slattery ML, Murtaugh M, Caan B, Ma KN, Neuhausen S, Samowitz W. Energy balance, insulin-related genes and risk of colon and rectal cancer. Int J Cancer. 2005;115:148-54.
19. Samowitz WS, Wolff RK, Ma KN, Andersen K, Caan B, Slattery ML. Polymorphisms in insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer. Mutat Res. 2006;595:117-24.
20. Slattery ML, Samowitz W, Curtin K, Ma KN, Hoffman M, Caan B, et al. Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1206-14.
21. Slattery ML, Samowitz W, Hoffman M, Ma KN, Levin TR, Neuhausen S. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev. 2004;13:538-45.
22. Slattery ML, Curtin K, Wolff R, Ma KN, Sweeney C, Murtaugh M, et al. PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control. 2006;17:239-49.
23. Dong X, Li Y, Tang H, Chang P, Hess KR, Abbruzzese JL, et al. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol. 2012;36:206-11.
24. Abulí A, Fernández-Rozadilla C, Alonso-Espinaco V, Muñoz J, Gonzalo V, Bessa X, et al. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer. 2011;11:339.
25. Saracevic A, Nikolac N, Reljic A, Simundic AM. Insulin receptor H1085H C > T and insulin receptor substrate 1 G972R polymorphisms and prostate cancer risk: a pilot study. Genet Test Mol Biomarkers. 2011;15:127-31.
26. Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, et al. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2009;18:282-8.
27. Ulybina IM, Imianitov EN, Vasil'ev DA, Bershten LM. Polymorphism of glucose intolerance and insulin resistance susceptibility genes in oncological patients. Mol Biol (Mosk). 2008;42:947-56.
28. Fall K, Stark JR, Mucci LA, Chan J, Stampfer MJ, Kurth T, et al. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate. 2008;68:1416-20.
29. Pechlivanis S, Pardini B, Bermejo JL, Wagner K, Naccarati A, Vodickova L, et al. Insulin pathway related genes and risk of colorectal cancer: INSR promoter polymorphism shows a protective effect. Endocr Relat Cancer. 2007;14:733-40.
30. Slattery ML, Sweeney C, Wolff R, Herrick J, Baumgartner K, Giuliano A, et al. Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Res Treat. 2007;104:197-209.
31. Li L, Cicek MS, Casey G, Witte JS. No association between genetic polymorphisms in insulin and insulin receptor substrate-1 and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2462-3.
32. Neuhausen SL, Slattery ML, Garner CP, Ding YC, Hoffman M, Brothman AR. Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: strong association of IRS1 G972R variant and cancer risk. Prostate. 2005;64:168-74.
33. Wagner K, Hemminki K, Grzybowska E, Klaes R, Butkiewicz D, Pamula J, et al. The insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect in breast cancer. Carcinogenesis. 2004;25:2473-8.
34. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273:1516-7.
35. Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004;20:439-44.
36. Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37:120-32.